A systematic review and meta-analysis of 10 studies to evaluate the efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis yielded mixed results, according to the findings published in Respiratory Research.
A systematic review and meta-analysis of 10 studies to evaluate the efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis (LAM) yielded mixed results, according to the findings published in Respiratory Research.
LAM is a low-grade multisystem neoplastic disease that results in cystic lung destruction, angiomyolipomas (AMLs), chylous fluid accumulation, and lymphangioleiomyomas. The disease, which almost exclusively affects adult females, can occur on its own or is associated with tuberous sclerosis complex. LAM is estimated to affect 5 in every 1 million people and has also been reported in adult males and children. For those in the end stage of the disease, lung transplantation is the only treatment option, but LAM can recur in transplanted lungs.
To conduct the review, researchers identified studies from sources such as PubMed, EMBASE, Cochrane Library, and others. In total, data from 330 patients enrolled in prospective clinical trials or randomized control trials were included in the review.
Pharmacological treatments included sirolimus, everolimus, doxycycline, triptorelin, and a combination of sirolimus and hydroxychloroquine. Adverse events and side effects occurred with each treatment option, but most “were reported to be low or moderate grade and were tolerable.”
Overall, the review supports “the application of sirolimus and everolimus in LAM, as these medications may stabilize lung function and alleviate renal AML.”
Specifically, 7 prospective studies reported that sirolimus was “effective at improving or stabilizing lung function and alleviating renal AML in LAM patients.” Three prospective studies on everolimus “reported similar effects…with regard to preserving lung function and reducing AMLs.” Researchers noted that further studies are required to determine the optimal timing, duration, and dosage of these treatments.
The review found no consistent evidence that doxycycline and triptorelin yielded any beneficial outcomes for patients, and further research needs to be conducted on the efficacy and safety of the combination therapy.
Researchers pointed out that because LAM is so rare, it is difficult to conduct the necessary studies needed to explore treatment options for the disease. “Generally, the prospect is still not optimistic in the treatment of LAM…the results of the current meta-analysis support only the opinion that [sirolimus and everolimus] are effective at stabilizing the condition,” the study authors noted.
However, results from 2 ongoing multicenter international trials “will help us better understand” the optimal usage of everolimus and sirolimus in patients with LAM, they wrote.
Reference
Qi W, Luo M, Xiang B, et al. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. Respir Res. 2020;21:55. doi: 10.1186/s12931-020-1316-3.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More